Format

Send to

Choose Destination
Bone Marrow Transplant. 2005 Nov;36(9):793-6.

Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation.

Author information

1
Department of Laboratory Hematology, Princess Margaret Hospital/University Health Network, University of Toronto, Toronto, Ontario, Canada. hong.chang@uhn.on.ca

Abstract

Genetic aberrations have emerged as major prognostic factors for patients with multiple myeloma (MM). We evaluated 126 MM patients for t(4;14) or t(11;14), 13q or p53 deletions and correlated the number of genetic aberrations with patient's clinical outcome following undergoing autologous stem cell transplantation. We demonstrate the significance of genetic-based risk classification that clearly segregate patients into low (no genetic abnormalities or only t(11;14)), intermediate (any one of the genetic abnormalities other than t(11;14)) and high-risk groups (any two or more of the genetic abnormalities other than t(11;14)). High-risk patients do not benefit from stem cell transplant and should be offered alternative therapies.

PMID:
16113669
DOI:
10.1038/sj.bmt.1705131
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center